Estrogen receptor and progesterone receptor expression in normal terminal duct lobular units surrounding invasive breast cancer

Breast Cancer Research and Treatment

Volumn 137, Issue 3, 2013, Pages 837-847

  Yang, Xiaohong R ^a   Figueroa, Jonine D ^a   Hewitt, Stephen M ^a   Falk, Roni T ^a   Pfeiffer, Ruth M ^a   Lissowska, Jolanta ^b   Peplonska, Beata ^c   Brinton, Louise A ^a   Garcia Closas, Montserrat ^a,d   Sherman, Mark E ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b INSTITUTE OF ONCOLOGY   (Poland)

^c NOFER INSTITUTE OF OCCUPATIONAL MEDICINE   (Poland)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Breast cancer; Estrogen receptor; Progesterone receptor; Risk factors; Terminal duct lobular units (TDLUs); Tumor characteristics

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; POLAND; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RISK FACTOR; TISSUE MICROARRAY; AGED; BREAST TUMOR; MAMMARY GLAND; MENOPAUSE; METABOLISM; MIDDLE AGED; PATHOLOGY; TUMOR INVASION;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; HUMANS; MAMMARY GLANDS, HUMAN; MENOPAUSE; MIDDLE AGED; NEOPLASM INVASIVENESS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK FACTORS;

MLCS; MLOWN;

EID: 84879376122     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-012-2380-2     Document Type: Article

References (35)

1. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA et al (2000) Molecular portraits of human breast tumours. Nature 406:747-752
2. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S et al (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100:8418-8423
3. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y et al (2012) The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486:346-352
4. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S et al (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295:2492-2502
5. Tamimi RM, Colditz GA, Hazra A, Baer HJ, Hankinson SE, Rosner B, Marotti J, Connolly JL, Schnitt SJ, Collins LC (2012) Traditional breast cancer risk factors in relation to molecular subtypes of breast cancer. Breast Cancer Res Treat 131:159-167
6. Graham K, de las Morenas A, Tripathi A, King C, Kavanah M, Mendez J, Stone M, Slama J, Miller M, Antoine G et al. (2010) Gene expression in histologically normal epithelium from breast cancer patients and from cancer-free prophylactic mastectomy patients shares a similar profile. Br J Cancer 102:1284-1293
7. Yan PS, Venkataramu C, Ibrahim A, Liu JC, Shen RZ, Diaz NM, Centeno B, Weber F, Leu YW, Shapiro CL et al (2006) Mapping geographic zones of cancer risk with epigenetic biomarkers in normal breast tissue. Clin Cancer Res 12:6626-6636
8. Trujillo KA, Hines WC, Vargas KM, Jones AC, Joste NE, Bisoffi M, Griffith JK (2011) Breast field cancerization: isolation and comparison of telomerase-expressing cells in tumor and tumor adjacent, histologically normal breast tissue. Mol Cancer Res 9:1209-1221
9. Heaphy CM, Griffith JK, Bisoffi M (2009) Mammary field cancerization: molecular evidence and clinical importance. Breast Cancer Res Treat 118:229-239
10. Graham K, Ge X, de Las Morenas A, Tripathi A, Rosenberg CL (2011) Gene expression profiles of estrogen receptor-positive and estrogen receptor-negative breast cancers are detectable in histologically normal breast epithelium. Clin Cancer Res 17:236-246
11. McKian KP, Reynolds CA, Visscher DW, Nassar A, Radisky DC, Vierkant RA, Degnim AC, Boughey JC, Ghosh K, Anderson SS et al (2009) Novel breast tissue feature strongly associated with risk of breast cancer. J Clin Oncol 27:5893-5898
12. Khan SA, Rogers MA, Obando JA, Tamsen A (1994) Estrogen receptor expression of benign breast epithelium and its association with breast cancer. Cancer Res 54:993-997
13. Khan SA, Rogers MA, Khurana KK, Meguid MM, Numann PJ (1998) Estrogen receptor expression in benign breast epithelium and breast cancer risk. J Natl Cancer Inst 90:37-42
14. Milanese TR, Hartmann LC, Sellers TA, Frost MH, Vierkant RA, Maloney SD, Pankratz VS, Degnim AC, Vachon CM, Reynolds CA et al (2006) Age-related lobular involution and risk of breast cancer. J Natl Cancer Inst 98:1600-1607
15. Yang XHR, Figueroa JD, Falk RT, Zhang H, Pfeiffer RM, Hewitt SM, Lissowska J, Peplonska B, Brinton L, Garcia-Closas M, Sherman ME (2012) Analysis of terminal duct lobular unit involution in luminal A and basal breast cancers. Breast Cancer Res 14
16. Garcia-Closas M, Brinton LA, Lissowska J, Chatterjee N, Peplonska B, Anderson WF, Szeszenia-Dabrowska N, Bardin-Mikolajczak A, Zatonski W, Blair A et al (2006) Established breast cancer risk factors by clinically important tumour characteristics. Br J Cancer 95:123-129
17. Yang XR, Sherman ME, Rimm DL, Lissowska J, Brinton LA, Peplonska B, Hewitt SM, Anderson WF, Szeszenia-Dabrowska N, Bardin-Mikolajczak A et al (2007) Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev 16:439-443
18. Yang XR, Charette LA, Garcia-Closas M, Lissowska J, Paal E, Sidawy M, Hewitt SM, Rimm DL, Sherman ME (2006) Construction and validation of tissue microarrays of ductal carcinoma in situ and terminal duct lobular units associated with invasive breast carcinoma. Diagn Mol Pathol 15:157-161
19. Sherman ME, Rimm DL, Yang XR, Chatterjee N, Brinton LA, Lissowska J, Peplonska B, Szeszenia-Dabrowska N, Zatonski W, Cartun R et al (2007) Variation in breast cancer hormone receptor and HER2 levels by etiologic factors: a population-based analysis. Int J Cancer 121:1079-1085
20. Tripathi A, King C, de la Morenas A, Perry VK, Burke B, Antoine GA, Hirsch EF, Kavanah M, Mendez J, Stone M et al (2008) Gene expression abnormalities in histologically normal breast epithelium of breast cancer patients. Int J Cancer 122:1557-1566
21. Walker RA, Cowl J, Dhadly PP, Jones JL (1992) Oestrogen receptor, epidermal growth factor receptor and oncoprotein expression in non-involved tissue of cancerous breasts. The Breast 28(1):34-37
22. Shoker BS, Jarvis C, Sibson DR, Walker C, Sloane JP (1999) Oestrogen receptor expression in the normal and pre-cancerous breast. J Pathol 188:237-244
23. Khan SA, Sachdeva A, Naim S, Meguid MM, Marx W, Simon H, Halverson JD, Numann PJ (1999) The normal breast epithelium of women with breast cancer displays an aberrant response to estradiol. Cancer Epidemiol Biomarkers Prev 8:867-872
24. Battersby S, Robertson BJ, Anderson TJ, King RJ, McPherson K (1992) Influence of menstrual cycle, parity and oral contraceptive use on steroid hormone receptors in normal breast. Br J Cancer 65:601-607
25. Markopoulos C, Berger U, Wilson P, Gazet JC, Coombes RC (1988) Oestrogen receptor content of normal breast cells and breast carcinomas throughout the menstrual cycle. Br Med J (Clin Res Ed) 296:1349-1351
26. Soderqvist G, von Schoultz B, Tani E, Skoog L (1993) Estrogen and progesterone receptor content in breast epithelial cells from healthy women during the menstrual cycle. Am J Obstet Gynecol 168:874-879
27. Lee O, Helenowski IB, Chatterton RT Jr, Jovanovic B, Khan SA (2012) Prediction of menopausal status from estrogen-related gene expression in benign breast tissue. Breast Cancer Res Treat 131:1067-1076
28. Horwitz KB, Koseki Y, McGuire WL (1978) Estrogen control of progesterone receptor in human breast cancer: role of estradiol and antiestrogen. Endocrinology 103:1742-1751
29. Key TJ, Appleby PN, Reeves GK, Roddam AW, Helzlsouer KJ, Alberg AJ, Rollison DE, Dorgan JF, Brinton LA, Overvad K et al (2011) Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studies. Br J Cancer 105:709-722
30. Hankinson SE, Eliassen AH (2010) Circulating sex steroids and breast cancer risk in premenopausal women. Horm Cancer 1:2-10
31. Smith FB, Puerto CD, Sagerman P (2001) Relationship of estrogen and progesterone receptor protein levels in carcinomatous and adjacent non-neoplastic epithelium of the breast: a histopathologic and image cytometric study. Breast Cancer Res Treat 65:241-247
32. Arpino G, Wiechmann L, Osborne CK, Schiff R (2008) Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev 29:217-233
33. Saeki T, Cristiano A, Lynch MJ, Brattain M, Kim N, Normanno N, Kenney N, Ciardiello F, Salomon DS (1991) Regulation by estrogen through the 5′-flanking region of the transforming growth factor alpha gene. Mol Endocrinol 5:1955-1963
34. Salomon DS, Brandt R, Ciardiello F, Normanno N (1995) Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19:183-232
35. Narod SA (2012) Breast cancer in young women. Nat Rev Clin Oncol 9:460-470